Interval debulking surgery for advanced epithelial ovarian cancer (Q24241193)

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

The role of interval debulking surgery in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Diagnostic open laparoscopy in the management of advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Interval cytoreduction in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Intervention debulking surgery in advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

The role of surgical reexploration following chemotherapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006014.PUB4

7 January 2021